These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21120581)

  • 1. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
    Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
    Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
    Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
    Muñoz M; Rosso M
    Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
    González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
    Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.
    Rosso M; Robles-Frías MJ; Coveñas R; Salinas-Martín MV; Muñoz M
    Tumour Biol; 2008; 29(4):245-54. PubMed ID: 18781096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138.
    Muñoz M; Rosso M; Coveñas R; Montero I; González-Moles MA; Robles MJ
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2775-81. PubMed ID: 17525212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
    Muñoz M; Rosso M; Coveñas R
    Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
    Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
    J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
    Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
    Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
    Muñoz M; Martinez-Armesto J; Coveñas R
    Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile.
    Muñoz M; Rosso M; González A; Saenz J; Coveñas R
    Peptides; 2010 Sep; 31(9):1643-8. PubMed ID: 20542069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of substance P and the NK-1 receptor in cancer progression.
    Muñoz M; Coveñas R
    Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor.
    Cascieri MA; Macleod AM; Underwood D; Shiao LL; Ber E; Sadowski S; Yu H; Merchant KJ; Swain CJ; Strader CD
    J Biol Chem; 1994 Mar; 269(9):6587-91. PubMed ID: 7509807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
    Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
    Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.